Record overview
Status and phase
Status: UNKNOWN
Phase: PHASE2
Sponsor: Consorzio Oncotech
Condition: Metastatic Breast Cancer
NCT05833919
Second Line ERIbulin Followed by CApecitabine or the Reverse Sequence in HER2-negative Metastatic Breast Cancer Patients
Public trial-level signal summary for this oncology Phase 2 record.
Signal summary
Public flags
Status signal: Unknown Status Signal
Timeline signals: stale_update_signal | primary_completion_date_past_signal | completion_date_past_signal
Results signal: Low Signal
Operational burden: strict_eligibility_signal
Stopped reason
Context when available
No stop reason available in the current public record.